GF 1006
Alternative Names: GF-1006Latest Information Update: 09 Oct 2025
At a glance
- Originator Genflow Biosciences
- Class Gene therapies; RNA
- Mechanism of Action Gene transference; SIRT6 protein expression modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Corneal disorders
Most Recent Events
- 07 Oct 2025 Preclinical trials in Corneal disorders in United Kingdom (Ophthalmic) (Genflow Biosciences pipeline, October 2025)